Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides

Infectious Disease Clinics of North America

Volumn 17, Issue 3, 2003, Pages 563-577

  Maglio, Dana ^a   Nicolau, David P ^a   Nightingale, Charles H ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZALIDE DERIVATIVE; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; KETOLIDE; LINCOSAMIDE; MACROLIDE; STREPTOGRAMIN; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; RESPIRATORY TRACT INFECTION; REVIEW;

EID: 0346433671     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(03)00059-X     Document Type: Review

References (55)

1. Mandell LA. Community-acquired pneumonia: etiology, epidemiology, and treatment. Chest 1995;108:35S-41S.
2. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin Infect Dis 2002;34(suppl 1):S4-S16.
3. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis 2003;45:251-9.
4. Doern GC, Heilmann KP, Huynk HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45:1721-9.
5. Labro MT. Cellular accumulation of macrolide antibiotics, intracellular bioactivity. In: Schonfeld W, Kirst HA, editors. Macrolide antibiotics. Basel: Birkhauser Verlag; 2002. p. 37-52.
6. Simonson JK, Amodio-Groton M. Macrolides and ketolides. Antibiotics for Clinicians 2003;7:165-71.
7. Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J Antimicrob Chemother 2003;51:947-55.
8. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
9. Barlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333: 1618-25.
10. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203.
11. Hoban DJ, Doern GV, Fluit AC, Roussel-Devallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S8-S93.
12. Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, et al., Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001;286:1857-62.
13. Sutcliffe JA, Leclerq R. Mechanisms of resistance to macrolides, lincosamides, and ketolides. In: Parnham MJ, Bruinvels J, editors. Macrolide antibiotics. Basel: Birkhauser Verlag; 2002. p. 281-317.
14. Kees F, Wallenhofer M, Grobecker H. Serum and cellular pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(suppl A):73-82.
15. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996;51:483-505.
16. Alvarez-Elcoro SS, Enzler MJ. The macrolides: erythromycin, clarithromycin and azithromycin. Mayo Clin Proc 1999;74:613-34.
17. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40:2375-9.
18. Conte JE, Golden JA, Duncan S, et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 1995;39:334-8.
19. Namour F, Wessels DH, Pascual MH, et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001;45:170-5.
20. Muller-Serieys C, Soler P, Cantalloube C, et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother 2001;45:3104-8.
21. Johnson JD, Hand WL, Franis B, et al. Antibiotic uptake by alveolar macrophages. J Lab Clin Med 1980;95:429-39.
22. Guay DR, Gustavson LE, Devcich KJ, Zhang J, Cao G, Olsen CA. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001;23:566-77.
23. Balfour JAB, Figgitt DA. Telithromycin. Drugs 2001;815-29.
24. Carbon C, Moola S, Velancsics I, Leroy B, Manickam R, Decosta P. Telithromycin (HMR 3647), a new once-daily ketolide antimicrobial, provides effective treatment of community acquired pneumonia [abstract 2245]. In: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto: American Society for Microbiology; 2000. p. 490.
25. Miossec-Bartoli C, Pilatre L, Peyron P, N'Diaye EN, Collart-Dutilleul V, Maridonneau-Parini I, et al. The new ketolide HMR 3647 accumulates in the azurophil granules of human polymorphonuclear cells. Antimicrob Agents Chemother 1999;43:2457-62.
26. Khair OA, Andrew JM, Honeybourne D, Jevons G, Vacheron F, Wise R. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001;47:837-40.
27. Alder JD, Ewing PJ, Nilius AM, Mitten M, Tovcimak A, Oleksijew A, et al. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. Antimicrob Agents Chemother 1998;42:2385-90.
28. Carbon C. Pharmacodynamics of macrolides, azalides, and streptograrnins: effect on extracellular pathogens. Clin Infect Dis 1998;27:28-32.
29. Nightingale CH, Owens RC Jr, Xu X, Quintiliani R, Nicolau DP. Comparative bactericidal activity of clarithromycin, azithromycin and cefuroxime against Streptococcus pneumoniae. J Infect Dis Pharmacother 1999;4:17-24.
30. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
31. den Hollender JG, Knudsen JD, Mouton JW, Fuursted K, Frimodt-Moller N, Verbrugh HA, et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob Agents Chemother 1998;42:377-82.
32. Novelli A, Fallani S, Cassetta MI, Arrigucci S, Mazzei T. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother 2002;14:584-90.
33. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997;9(suppl 3): 38-44.
34. Odenholt-Tornqvist I, Lowden E, Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 1995;39:221-6.
35. Bergman KL, Olsen KM, Peddicord TE, Fey PD, Rupp ME. Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid againt clinical isolates of Haemophilus influenzae and Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:1291-3.
36. Periti P, Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J Chemother 1999;11:11-27.
37. Parazzoli A, Marcella P, Broggio R, Marturano MB, Di Modugno E. Time- or concentration-dependent efficacy of clarithromycin using S. pneumoniae strains with different phenotypes [abstract 5.07]. In: Programs and abstracts of the 6th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones. Bologna, Italy: American Society for Microbiology; 2002. p. 136,
38. Tessier PR, Kim MK, Zhou W, Xuan D, Li C, Ye M, et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumoniae. Antimicrob Agents Chemother 2002;46:1425-34.
39. Boswell FJ, Andrew JM, Wise R. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother 1998; 41:149-53.
40. Tessier PR, Mattoes HM, Dandekar PK, Nightingale CH, Nicolau DP. Pharmacodynamic profile of telithromycin against macrolide and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic thigh infection model. Antimicrob Agents Chemother, in press.
41. Craig WA, Andes DR. Differences in the in vivo pharmacodynamics of telithromycin and azithromycin against Streptococcus pneumoniae [abstract 2141]. In: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto: American Society for Microbiology; 2000. p. 32.
42. Kim M, Zhou W, Tessier P, Xuan D, Ye M, Nightingale CH, et al. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob Agents Chemother 2002;46:3185-92.
43. Capitano B, Maglio D, Banevicius MA, Nightingale CH, Nicolau DP. Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model. Int J Antimicrob Agents, in press.
44. Nightingale CH, Mattoes HM. Macrolide, azalide and ketolide pharmacodynamics. In: Nightingale CH, Murakawa T, Ambrose P, editors. Antimicrobial pharmacodynamics in theory and clinical practice. New York: Marcel Decker; 2002. p. 205-20.
45. Nicolau DP. Antibiotic kinetic and dynamic attributes for community-acquired respiratory tract infections. Am J Manag Care 2000;6:S1202-10.
46. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:944-8.
47. Stein GE, Scholley S. Serum bactericidal activity of extended-release clarithromycin against macrolides-resistant strains of Streptococcus pneumoniae. Pharmacotherapy 2002; 22:593-6.
48. Bauernfeind A, Jungwirth R, Eberlein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection 1995;23:316-21.
49. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001;33(suppl 3):S187-92.
50. Nicolau DP. Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. J Antimicrob Chemother 2002;50(suppl S1):61-70.
51. Drusano GL, Preston SL. Utility of an 800 mg dose of telithromycin for community-acquired pneumonia caused by extracellular pathogens: an assessment by pharmacodynamic modeling and Monte Carlo simulation [poster 1364]. Presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, April 24-27, 2002.
52. Noreddin AM, Roberts D, Nichol K, Wierzbowski A, Hoban DJ, Zhanel GG. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother 2002; 46:4029-34.
53. Hoffman HL, Klepser ME, Ernst EJ, Petzold CR, Sa'adah LM, Doern GV. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 2003;47:739-46.
54. Bui KQ, Banevicius MA, Nightingale CH, Quintiliani R, Nicolau DP. In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;45:57-62.
55. Fuursted K, Knudsen JD, Petersen MB, et al. Comparative study of bactericidal activities, postantibiotic effects, and effects of bacterial virulence of penicillin G and six macrolides against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:781-4.